Over-the-counter PPIs should be taken for only 14 days for treatment of frequent heartburn.
在市场上买的质子泵抑制剂用来治疗频发的烧心症时只能使用14天。
Patients taking PPIs daily had a 74% increased risk compared with those not taking the drugs.
每天服用质子泵抑制剂的病人受感染的风险比不服用药物的增加了74%。
In most cases reviewed the patients did not continue on PPIs after the hypomagnesemia was treated.
大多数病例在低镁血症得到治疗后没有继续使用质子泵抑制剂。
Objective to clarify whether proton pump inhibitors (PPIs) stimulate Cyclooxygenase-2 (COX-2) expression in rat gastric mucosa.
目的探讨质子泵抑制剂(PPI)对大鼠胃粘膜环氧化酶—2 (COX - 2)表达的影响。
Lansoprazole (LPZ) that has been widely used for the treatment of acid-related diseases is a relatively novel class of proton pump inhibitors (PPIs).
兰索拉唑(LPZ)是近年来开发并已被广泛用于治疗胃酸相关性疾病的新型质子泵抑制剂。
Further research showed using PPIs along with Plavix did not lead to any significant increase in the risk of heart disease events like heart attack or stroke.
进一步的研究显示质子泵抑制剂与波利维一起没有导致像心肌梗塞或中风等心脏病事件风险的显著增加。
Information about the potential risk of low serum magnesium levels from PPIs will be added to the WARNINGS AND PRECAUTIONS sections of the labels for all the prescription PPIs.
这些处方药类质子泵抑制剂标签WARNINGSANDPRECAUTIONS部分将增加这类药物引发低镁血症风险的信息。
But recent reports had suggested that there might be a potentially dangerous interaction between the two drug classes whereby PPIs reduce the actual effectiveness of antiplatelet agents.
但是近期的报道已经表明两种药物之间有潜在危险的相互作用，由此质子泵抑制剂降低抗血小板药物的实际效果。
Advise patients to seek immediate care from a healthcare professional if they experience arrhythmias, tetany, tremors, or seizures while taking PPIs. These may be signs of hypomagnesemia.
应建议患者服用质子泵抑制剂后如果出现心律失常、抽搐、或者癫痫等症状应及时就医。这些症状可能是低镁血症的征兆。
This is considered an off-label (unapproved) use. Healthcare professionals should communicate the risk of hypomagnesemia to patients if they are recommending prolonged use of an OTC PPIs.
如果医疗保健专业人员建议患者如此延长非处方类质子泵抑制剂使用的时间，应当与患者沟通由此可能发生的低镁血症的风险。
Since the first proton pump inhibitor (Omeprazole) came into the market in 1988, PPIs have been considered as the drugs of first choice for treatment of patients with various acid-related diseases.
自第一个质子泵抑制剂(PPI)奥美拉唑于1988年上市以来，PPI已成为酸相关性疾病治疗的首选药物。
Since the first proton pump inhibitor (Omeprazole) came into the market in 1988, PPIs have been considered as the drugs of first choice for treatment of patients with various acid-related diseases.
自第一个质子泵抑制剂(PPI)奥美拉唑于1988年上市以来，PPI已成为酸相关性疾病治疗的首选药物。
应用推荐